ANTI TUMOUR TREATMENTAdvances in the treatment of non-small cell lung cancer
Section snippets
First-line chemotherapy
The efficacy of lung cancer chemotherapy with cytotoxic anticancer agents has reached a plateau,2, 3, 4 and under the present circumstances it is difficult to expect any cytotoxic novel anticancer agents to become available although some hope exists in assessment of the efficacy of pemetrexed against adenocarcinoma,5 the significance of TS1,6, etc. The statement of “the results of treatment with 2-drug combinations consisting of cisplatin (CDDP) or carboplatin (CBDCA) and a new drug are the
Expectations of molecularly targeted therapy
When Epidermoid Growth Factor Receptor Thyrosine kinase Inhibitors (EGFR-TKIs) became available, a great progress was expected in the treatment of non-small cell lung cancer.14, 15 However, lung cancer investigators were surprised to find that according to the results of the Iressa NSCLC trial Assessing Combination Treatment (INTACT) 1 and 2 studies16, 17 and the TALENT and TRIBUTE studies18, 19 EGFR-TKIs provided no efficacy in addition to standard chemotherapy. Because the response rate to
Adjuvant chemotherapy
The field of adjuvant chemotherapy in non-small cell lung cancer has changed totally over the last 5 years. Until ASCO2003, there was no evidence except for a meta-analysis of MRC, that chemotherapy may have a role. However, beginning with the presentation of International Adjuvant Lung Cancer Trial (IALT) study by LeChavalier,40 there have been five randomized controlled studies that have been reported to show improved survival. According to the Lung Adjuvant Cisplatin Evaluation (LACE)
Conflict of interest statement
I have no potential conflict of interest to disclose except for stock option of Takeda pharmaceutical company.
References (57)
- et al.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: FACS in Japan
Ann Oncol
(2007) - et al.
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA NSCLC, ANITA trial
Lancet Oncol
(2006) - et al.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Lancet
(2005) - et al.
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study
J Thoracic Oncol
(2006) - et al.
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 NSCLC (JCOG9209)
J Thorac Cardiov Surg
(2003) - et al.
Final results of phase III trial in regionally advanced unresectable NSCLC: RTOG, ECOG, and SWOG
Chest
(2000) Recent trends in the treatment of advanced lung cancer
Cancer Sci
(2006)- et al.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
N Engl J Med
(2002) - et al.
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced NSCLC: a SWOG trial
J Clin Oncol
(2001) - et al.
Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer
J Thorac Oncol
(2007)
Phase II study of S1, a novel oral fluorouracil, in advanced NSCLC
Brit J Cancer
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the Tax 326 study group
J Clin Oncol
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV NSCLC: the Japanese Taxotere Lung Cancer Study Group
J Clin Oncol
Vinorelbine plus cisplatin vs observation in resected NSCLC
New Engl J Med
A randomized trial of adjuvant chemotherapy with UFT for adenocarcinoma of the lung
New Engl J Med
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced NSCLC
J Clin Oncol
Cisplatin vs carboplatin for patients with metastatic NSCLC—An old rivalry renewed
J Natl Cancer Inst
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in NSCLC and other solid tumors: results of a phase I trial
J Clin Oncol
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced NSCLC (The IDEAL 1 Trial)
J Clin Oncol
Gefitinib in combination with gemcitabine and cisplatin in advanced NSCLC: a phase III trial—INTACT 1
J Clin Oncol
Gefitinib in combination with paclitaxel and carboplatin in advanced NSCLC: a phase III trial—INTACT 2
J Clin Oncol
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced NSCLC
J Clin Oncol
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced NSCLC: TALENT trial
Proc ASCO
EGFR inhibitors: what have we learned from the treatment of lung cancer?
Nat Clin Oncol
Phase III study (V-15-32) of gefitinib versus docetaxel in previously treated Japanese patients with NSCLC
Proc ASCO
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
J Clin Oncol
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
J Natl Cancer Inst
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
J Clin Oncol
Cited by (8)
EGFR-TKIS combined with radioactive <sup>125</sup>I seed implantation for the treatment of advanced nonsmall-cell lung cancer: Analysis of clinical effect
2015, Journal of Interventional Radiology (China)Cancer patients use hospital-based care until death: A further analysis of the dutch bone metastasis study
2011, Journal of Palliative MedicineLung cancer working group report
2010, Japanese Journal of Clinical OncologyProgress in cancer chemotherapy with special stress on molecular-targeted therapy
2010, Japanese Journal of Clinical OncologyPathogenesis of lung cancer signalling pathways: Roadmap for therapies
2009, European Respiratory Journal